美国FDA医疗器械智慧监管现状与启示

摘要/Abstract

摘要： 新技术、新材料、新工艺的井喷式涌现使得医疗器械产业呈现多元创新的发展态势，传统的监管方式难以适应医疗器械产业快速发展的需要，世界各国都在积极探索信息化监管方式。我国也要与时俱进，利用现代科技手段推动监管创新，打造医疗器械监管信息化平台，推动实现“互联网+监管”的智慧监管模式，提高我国医疗器械监管效能。为此，本研究对美国食品药品管理局信息化战略规划及医疗器械智慧监管情况进行了梳理，并结合我国药监部门智慧监管体系的发展现状，提出提升策略，包括优化顶层设计、共建共享共治、深挖数据价值，期望对我国医疗器械智慧监管体系建设起到启示作用。

关键词: font-size:medium, ">医疗器械；FDA；信息化；智慧监管

Abstract: The rapid emergence of new technologies， new materials， and new processes has led to a diversified and innovative development trend of medical device industry. Traditional supervisory approaches are unable to keep up with the rapid development of the medical device industry， and countries around the world are actively exploring informatization supervision mode. China should also keep pace with the times， use modern technology to promote supervisory innovation， create the information platform for medical device supervision， and promote the smart supervisory model of “Internet + supervision” to improve the efficiency of medical device supervision. Therefore， this study reviewed the information technology strategic plans and smart supervisory situation of the US Food and Drug Administration (FDA)， combined with the development status of smart supervision sytem of China′s drug regulatory departments， and proposed improvement strategies， including optimizing top-level design， co-building， sharing and co-governance， and exploring the value of data， so as to provide inspiration for the construction of China′s medical device smart supervision system.

Key words: font-size:medium, ">Medical devices； FDA； Informatization； Smart supervision

中图分类号:

曾美琪, 连小奇. 美国FDA医疗器械智慧监管现状与启示[J]. 中国医药导刊, 2023, 25(6): 565-569.

ZENG Meiqi, LIAN Xiaoqi. The Current Situation of US FDA′s Smart Supervision of Medical Devices and Its Implication[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2023, 25(6): 565-569.

参考文献

[1]国家药品监督管理局. 国家药监局关于印发《药品监管网络安全与信息化建设“十四五”规划》的通知 [EB/OL]. (2022-04-24) [2023-04-25]. https：//www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjzh/20220511110329171.html.
     [2]FDA. Information Technology Strategic Plan 2015-2018 [EB/OL]. [2023-05-25]. https：//www.fda.gov/media/84489/download.
     [3]FDA. FDA’s Technology Modernization Action Plan [EB/OL]. (2019-09-17) [2023-04-25]. https：//www.fda.gov/about-fda/reports/fdas-technology-modernization-action-plan.
     [4]FDA. Data Modernization Action Plan [EB/OL]. (2021-03-03) [2023-04-25]. https：//www.fda.gov/about-fda/reports/data-modernization-action-plan.
     [5]FDA. Office of Digital Transformation [EB/OL]. (2023-03-15) [2025-04-25]. https：//www.fda.gov/about-fda/office-commissioner/office-digital-transformation.
     [6]FDA. Enterprise Modernization Action Plan [EB/OL]. (2022-05-19) [2023-04-25]. https：//www.fda.gov/about-fda/office-digital-transformation/enterprise-modernization-action-plan.
     [7]杨依晗,王广平,王颖. 美国FDA现代化行动计划简述及启示[J].中国医药导刊, 2022, 24(10):1028-1033.
     [8]FDA. Cybersecurity Modernization Action Plan [EB/OL]. (2022-11-17) [2023-04-25]. https：//www.fda.gov/about-fda/office-digital-transformation/cybersecurity-modernization-action-plan.
     [9]FDA. Leadership Modernization Action Plan [EB/OL]. (2022-12) [2023-04-25]. https：//www.fda.gov/media/163709/download.
     [10]FDA. Office of Digital Transformation Strategic Plan 2023-2025 [EB/OL]. (2022-12) [2023-04-25]. https：//www.fda.gov/media/163918/download.
     [11]FDA. How CDRH’s Digital Transformation Initiative Will Strengthen the Premarket Review Program [EB/OL]. (2021-10-24) [2023-04-25]. https：//www.fda.gov/news-events/fda-voices/how-cdrhs-digital-transformation-initiative-will-strengthen-premarket-review-program.
     [12]FDA. Device Registration and Listing Module (DRLM)： Step-by-Step Instructions [EB/OL]. (2016-07) [2023-04-25]. https：//www.access.fda.gov/drlm/help/index.html.
     [13]FDA. FDA eSubmitter [EB/OL]. (2022-10-04) [2023-04-25]. https：//www.fda.gov/industry/fda-esubmitter.
     [14]FDA. eCopy Program for Medical Device Submissions [EB/OL]. (2020-04-27) [2023-04-25]. https：//www.fda.gov/media/83522/download.
     [15]FDA. Electronic Submission Template for Medical Device 510(k) Submissions [EB/OL]. (2022-09-22) [2023-04-25]. https：//www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-template-medical-device-510k-submissions.
     [16]FDA. Send and Track Medical Device Premarket Submissions Online： CDRH Portal [EB/OL]. (2023-05-22) [2023-04-25]. https：//www.fda.gov/medical-devices/industry-medical-devices/send-and-track-medical-device-premarket-submissions-online-cdrh-portal.
     [17]FDA. About Manufacturer and User Facility Device Experience (MAUDE) [EB/OL]. (2023-02-02) [2023-04-25]. https：//www.fda.gov/medical-devices/mandatory-reporting-requirements-manufacturers-importers-and-device-user-facilities/about-manufacturer-and-user-facility-device-experience-maude.
     [18]FDA. Electronic Medical Device Reporting (eMDR) [EB/OL]. (2018-03-29) [2023-04-25]. https：//www.fda.gov/industry/fda-esubmitter/electronic-medical-device-reporting-emdr.
     [19]FDA. MedSun： Medical Product Safety Network [EB/OL]. (2020-12-16) [2023-04-25]. https：//www.fda.gov/medical-devices/medical-device-safety/medsun-medical-product-safety-network.
     [20]FDA. MedWatch： The FDA Safety Information and Adverse Event Reporting Program [EB/OL]. (2023-05-24) [2023-04-25]. https：//www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program.
     [21]FDA. 522 Postmarket Surveillance Studies Program [EB/OL]. (2022-10-06) [2023-04-25]. https：//www.fda.gov/medical-devices/postmarket-requirements-devices/522-postmarket-surveillance-studies-program.
     [22]FDA. Post-Approval Studies Program [EB/OL]. (2022-10-06) [2023-04-25]. https：//www.fda.gov/medical-devices/postmarket-requirements-devices/post-approval-studies-program.
     [23]FDA. How to Request Export Certificates or Permits and How To Submit Simple Notifications [EB/OL]. (2020-11-06) [2023-04-25]. https：//www.fda.gov/medical-devices/exporting-medical-devices/how-request-export-certificates-or-permits-and-how-submit-simple-notifications#submit.
     [24]FDA. GUDID Guidance [EB/OL]. (2021-10-13) [2023-04-25]. https：//www.fda.gov/medical-devices/global-unique-device-identification-database-gudid/gudid-guidance.
     [25]FDA. CDRH Transparency： Total Product Life Cycle (TPLC) [EB/OL]. (2018-09-06) [2025-04-25]. https：//www.fda.gov/about-fda/cdrh-transparency/cdrh-transparency-total-product-life-cycle-tplc.
     [26]FDA. National Evaluation System for health Technology (NEST) [EB/OL]. (2019-10-29) [2023-04-25]. https：//www.fda.gov/about-fda/cdrh-reports/national-evaluation-system-health-technology-nest.
     [27]国家药品监督管理局. 国家药监局关于印发《国家药品监督管理局关于加快推进药品智慧监管的行动计划》的通知 [EB/OL]. (2019-05-21) [2023-04-25]. http：//www.gov.cn/zhengce/zhengceku/2019-09/26/content_5433485.htm.
     [28]赵宇，王景涛，梁庆涛. 医疗器械唯一标识系统实践浅析[J]. 中国食品药品监管， 2022，(6)：74-79.
     [29]叶友学，杨皎，张冬雪，等. 基层医疗器械智慧监管新模式探索[J]. 中国食品药品监管， 2022，(4)：120-125.
     [30]严欣哲. 医药健康便民服务数字化改革探索与实践——以椒江区“三医”联动应用为例[J]. 中国食品药品监管， 2022，(10)：96-103.
     [31]陈蕾，李梦. 我国医疗器械监管信息化的探讨[J]. 中国医疗器械杂志， 2017，41(4)：275-278，294.
     [32]郭艳，庆凌，关怀. 中美医疗器械上市后监管模式对比[J]. 中国药业， 2023，32(6)：4-7.
     [33]余超，徐玉茗，罗培，等. 基于改良德尔菲的医疗器械不良事件报告质量评估体系研究探索[J]. 中国医疗器械信息， 2021，27(1)：11-27.

快速检索引用检索图表检索高级检索